Research Analysts’ Recent Ratings Updates for BridgeBio Pharma (BBIO)

BridgeBio Pharma (NASDAQ: BBIO) recently received a number of ratings updates from brokerages and research firms:

• 3/18/2026 – BridgeBio Pharma had its price target raised by Mizuho from $91.00 to $106.00. They now have an “outperform” rating on the stock.
• 3/12/2026 – BridgeBio Pharma had its “outperform” rating reaffirmed by Leerink Partners. They now have a $98.00 price target on the stock.
• 3/10/2026 – BridgeBio Pharma had its “overweight” rating reaffirmed by Barclays PLC.
• 3/10/2026 – BridgeBio Pharma had its price target raised by JPMorgan Chase & Co. from $89.00 to $94.00. They now have an “overweight” rating on the stock.
• 3/10/2026 – BridgeBio Pharma is now covered by William Blair. They set an “outperform” rating on the stock.
• 2/25/2026 – BridgeBio Pharma had its price target lowered by Oppenheimer Holdings, Inc. from $83.00 to $81.00. They now have an “outperform” rating on the stock.
• 2/25/2026 – BridgeBio Pharma had its price target raised by Truist Financial Corporation from $86.00 to $95.00. They now have a “buy” rating on the stock.
• 2/25/2026 – BridgeBio Pharma had its price target raised by Morgan Stanley from $96.00 to $98.00. They now have an “overweight” rating on the stock.
• 2/17/2026 – BridgeBio Pharma had its price target raised by HC Wainwright from $90.00 to $100.00. They now have a “buy” rating on the stock.
• 2/13/2026 – BridgeBio Pharma had its price target raised by Oppenheimer Holdings, Inc. from $81.00 to $83.00. They now have an “outperform” rating on the stock.
• 2/13/2026 – BridgeBio Pharma had its price target raised by Wells Fargo & Company from $88.00 to $98.00. They now have an “overweight” rating on the stock.
• 2/12/2026 – BridgeBio Pharma was given a new $89.00 price target by Raymond James Financial, Inc.. They now have an “outperform” rating on the stock.
• 1/28/2026 – BridgeBio Pharma is now covered by Barclays PLC. They set an “overweight” rating on the stock.
• 1/21/2026 – BridgeBio Pharma had its “sell (d-)” rating reaffirmed by Weiss Ratings.
• 1/20/2026 – BridgeBio Pharma had its price target raised by Wells Fargo & Company from $84.00 to $88.00. They now have an “overweight” rating on the stock.

Insiders Place Their Bets

In related news, Director Andrea Ellis sold 64,921 shares of the firm’s stock in a transaction on Wednesday, March 4th. The stock was sold at an average price of $64.87, for a total value of $4,211,425.27. Following the transaction, the director owned 18,589 shares in the company, valued at approximately $1,205,868.43. This trade represents a 77.74% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, CFO Thomas Trimarchi sold 13,600 shares of the stock in a transaction dated Tuesday, February 17th. The stock was sold at an average price of $74.72, for a total transaction of $1,016,192.00. Following the sale, the chief financial officer owned 336,585 shares in the company, valued at $25,149,631.20. The trade was a 3.88% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold a total of 237,084 shares of company stock valued at $16,608,419 in the last quarter. Company insiders own 18.20% of the company’s stock.

BridgeBio Pharma, Inc is a clinical-stage biopharmaceutical company headquartered in Palo Alto, California. Founded in 2015 by Neil Kumar, the company is dedicated to discovering, developing and delivering transformative medicines for patients with genetic diseases and cancers. BridgeBio operates an integrated model that spans target identification, preclinical research, clinical development and commercialization, aiming to streamline the process from bench to bedside.

BridgeBio’s pipeline comprises multiple therapeutic modalities, including small molecules, biologics and genetic therapies.